Where does YDES stock trade?

YD Bio Limited (YDES) is listed on NASDAQ.

What sector and industry is YDES in?

YD Bio Limited operates in the Health Care sector, Medical Specialities industry.

What companies are similar to YDES?

Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare YDES side-by-side with any of them on Quantisnow.

How can I track YDES on Quantisnow?

Quantisnow aggregates YD Bio Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YDES to receive live email and push alerts on every new disclosure.

YDES

NASDAQ

YD Bio Limited

SectorHealth CareIndustryMedical Specialities

$3.86+0.92 (+31.29%)

News25/Ratings0

Price$3.86+0.12 (+3.21%)

03:00 PM05:45 PM

News · 26 weeks30-33%

2025-12-072026-05-31

Mix1590d

Insider9(60%)
Other4(27%)
Earnings1(7%)
SEC Filings1(7%)

Latest news

25 items

2dSEC
SEC Form EFFECT filed by YD Bio Limited
EFFECT - YD Bio Ltd (0002011674) (Filer)
7dSEC
SEC Form POS AM filed by YD Bio Limited
POS AM - YD Bio Ltd (0002011674) (Filer)
33dPR
YD Bio Limited Reports Full Year 2025 Financial Results
TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary"2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengt
33dSEC
SEC Form 20-F filed by YD Bio Limited
20-F - YD Bio Ltd (0002011674) (Filer)
44dINSIDER
Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
3/A - YD Bio Ltd (0002011674) (Issuer)
61dINSIDER
SEC Form 4 filed by Lu Shao-Ta
4 - YD Bio Ltd (0002011674) (Issuer)
61dINSIDER
SEC Form 4 filed by Chang Kochi
4 - YD Bio Ltd (0002011674) (Issuer)
61dINSIDER
SEC Form 3 filed by new insider Lu Shao-Ta
3 - YD Bio Ltd (0002011674) (Issuer)
62dINSIDER
SEC Form 3 filed by new insider Chang Kochi
3 - YD Bio Ltd (0002011674) (Issuer)
64dPR
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company ("EG BioMed"), officially launched the EG Telehealth Platform, https://mdi.eg-bio.com, which marks a significant milestone in the Company's commercialization of early cancer detection and decentralized clinical service delivery across the United States. The platform is now live and enables access across 44 U.S. states, plus Washington, D.C. and Guam, supported by a nationwide network
64dINSIDER
SEC Form 3 filed by new insider Lee Jerry Yin-Chia
3 - YD Bio Ltd (0002011674) (Issuer)
67dINSIDER
SEC Form 3 filed by new insider Zhang Bo-Xiang
3 - YD Bio Ltd (0002011674) (Issuer)
68dINSIDER
SEC Form 3 filed by new insider Hen Man Edmund
3 - YD Bio Ltd (0002011674) (Issuer)
77dINSIDER
SEC Form 3 filed by new insider Shen Ethan Phd
3 - YD Bio Ltd (0002011674) (Issuer)
78dPR
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
Taipei, Taiwan, March 17, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech
96dSEC
SEC Form 424B3 filed by YD Bio Limited
424B3 - YD Bio Ltd (0002011674) (Filer)
96dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
98dPR
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. ("YD Bio USA") entered into a Master Strategic Alliance Agreement (the "Agreement") with YC Biotech Co., Ltd. ("YC Biotech") on February 24, 2026. This partnership represents a pivotal advancement in the Company's mission, establishing YD Bio USA as the official strategic hub and exclusive U.S. Agent for regulatory applications to the U.S. Food and Drug Administration (the "FDA") for YC Biotech's Contract Research
117dSEC
SEC Form 424B3 filed by YD Bio Limited
424B3 - YD Bio Ltd (0002011674) (Filer)
124dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
125dPR
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio Ltd" or the "Company") (NASDAQ:YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced it has entered into a binding Letter of Intent (the "LoI") to acquire all shares, assets, and business of Safe Save Medical Cell Sciences & Technology Co., Ltd. ("SSMC"), a Taiwan-based dendritic cell immunotherapy platform. The LoI, executed on January 20, 2026, signifies a definitive step towards integrating SSMC's advanced immunocell therapy capabilities into YD Bio Ltd's strategic portfolio, further solidifying the Company's strategic transformation from
133dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
138dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
139dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)
148dSEC
SEC Form 6-K filed by YD Bio Limited
6-K - YD Bio Ltd (0002011674) (Filer)

YDES FAQ

4 questions

Where does YDES stock trade?
YD Bio Limited (YDES) is listed on NASDAQ.
What sector and industry is YDES in?
YD Bio Limited operates in the Health Care sector, Medical Specialities industry.
What companies are similar to YDES?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare YDES side-by-side with any of them on Quantisnow.
How can I track YDES on Quantisnow?
Quantisnow aggregates YD Bio Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow YDES to receive live email and push alerts on every new disclosure.